Overview

LEA29Y (Belatacept) Emory Edmonton Protocol

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to determine the safety and effectiveness of islet transplantation using a steroid-free, calcineurin-inhibitor-free belatacept based immunosuppressive medication, for treating type 1 diabetes in individuals experiencing hypoglycemia unawareness and severe hypoglycemic episodes.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Clinical Islet Transplantation Consortium
Treatments:
Abatacept
Basiliximab
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus